Of deals by the top companies in the sector, 140 were at the preclinical development stage, with an average of $22.9m invested, followed by 39 investments at phase I, 34 at phase II and 13 at phase III, although the average amounts invested increased by stage.
The top 50 healthcare companies’ corporate venturing units have predominantly invested in portfolio companies testing their products at the preclinical stage over the past decade.
Farhang Modaresi and Parhat Hebibul, master students in Finland-based Karolinska Institutet’s bioentrepreneurship programme, in a report commissioned by Stockholm Business Region (pictured) looked at more than 300 deals by the top 50 healthcare companies, of which nearly 60% had a corporate venturing unit.
Of the deals, 140 were at the preclinical development stage, with…
